Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells
- PMID: 16394018
- DOI: 10.4049/jimmunol.176.2.1266
Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells
Abstract
CD4+CD25+ immunoregulatory T cells (Tregs) can be administered to inhibit graft-vs-host disease (GVHD) while preserving graft-vs-leukemia activity after allogeneic bone marrow transplantation in mice. Preclinical studies suggest that it is necessary to infuse as many Tregs as conventional donor T cells to achieve a clinical effect on GVHD. Thus, it would be necessary to expand Tregs ex vivo before transplantation. Two strategies have been proposed: expansion of Tregs stimulated by anti-CD3/CD28-coated microbeads for polyclonal activation or by host-type allogeneic APCs for selecting Tregs specific for host Ags. In this study, we describe the mechanisms by which ex vivo-expanded Tregs act on donor T cells to prevent GVHD in mice. We demonstrate that expanded Tregs strongly inhibited the division, expansion, and differentiation of donor T cells, with a more pronounced effect with Tregs specific for host Ags. These latter cells permit the efficient and durable control of GVHD and favor immune reconstitution.
Similar articles
-
Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.Transplant Proc. 2011 Jun;43(5):2041-8. doi: 10.1016/j.transproceed.2011.02.055. Transplant Proc. 2011. PMID: 21693322
-
Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.Blood. 2015 Jul 23;126(4):546-57. doi: 10.1182/blood-2015-04-637587. Epub 2015 Jun 10. Blood. 2015. PMID: 26063163 Free PMC article.
-
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.Nat Med. 2003 Sep;9(9):1144-50. doi: 10.1038/nm915. Epub 2003 Aug 17. Nat Med. 2003. PMID: 12925844
-
Reconstructing immunity after allogeneic transplantation.Immunol Res. 2004;29(1-3):269-82. doi: 10.1385/IR:29:1-3:269. Immunol Res. 2004. PMID: 15181288 Review.
-
Regulatory T Cells in GVHD Therapy.Front Immunol. 2021 Jun 18;12:697854. doi: 10.3389/fimmu.2021.697854. eCollection 2021. Front Immunol. 2021. PMID: 34220860 Free PMC article. Review.
Cited by
-
Treatment of graft-versus-host disease with naturally occurring T regulatory cells.BioDrugs. 2013 Dec;27(6):605-14. doi: 10.1007/s40259-013-0050-5. BioDrugs. 2013. PMID: 23813436 Free PMC article. Review.
-
Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy.Front Immunol. 2023 Mar 20;14:1082727. doi: 10.3389/fimmu.2023.1082727. eCollection 2023. Front Immunol. 2023. PMID: 37020562 Free PMC article.
-
Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity.Front Immunol. 2019 Jan 31;10:43. doi: 10.3389/fimmu.2019.00043. eCollection 2019. Front Immunol. 2019. PMID: 30804926 Free PMC article. Review.
-
Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells.PLoS One. 2008 Sep 26;3(9):e3289. doi: 10.1371/journal.pone.0003289. PLoS One. 2008. PMID: 18818761 Free PMC article.
-
Regulatory T-cell immunotherapy for allogeneic hematopoietic stem-cell transplantation.Ther Adv Hematol. 2012 Feb;3(1):29-44. doi: 10.1177/2040620711422266. Ther Adv Hematol. 2012. PMID: 23556110 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous